Experimental validation for the use of recombinant prourokinase and its immobilized forms in the treatment of postoperative fibrinoid syndrome in ophthalmology

The specific therapeutic effectiveness of a single intravitreal injection of native and immobilized recombinant prourokinase is assessed in lensvitrectomized rabbits with the fibrinoid syndrome. The agents almost completely lyse the fibrin clot within 1–8 h. Heteroprotein conjugates of protein kinase with molecular weight of 900 kD and high fibrinolytic activity at 2–20-fold lower doses of the enzyme are preferable. Native and immobilized prourokinase are recommended for clinical use in case of intraocular fibrin formation after lensvitrectomy and other operations.